We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

World’s First Test Kit Detects Omicron Variant by Combining Gene Dropout and Mutations Specific Detection

By LabMedica International staff writers
Posted on 10 Jan 2022
Print article

The world’s first test kit that can detect the B.1.1.529 (Omicron) variant by combining S-gene target failure (SGTF) and S-gene mutation amplification (SGMA) promises to cut down procedural delays in genome sequencing to ascertain the latest SARS-CoV-2 variant.

Tata Medical & Diagnostic Centre (Tamil Nadu, India) has developed the first-of-its-kind RT-PCR test kit dubbed OmiSure that can capture both the gene dropout and specific mutation to detect the Omicron variant of COVID-19 on nasal and oral swab samples. The test is compatible with all common Real-Time PCR devices and has been approved by India’s regulatory body, the Indian Council of Medical Research (ICMR). It has been designed to pick up all SARS-CoV-2 variants, but specifically pulls out Omicron. The test takes about 2.5 hours from specimen collection to reporting and can be performed in all RT-PCR labs without the need for any special training.

OmiSure is a real time PCR test and not a home testing kit as it detects viral genetic material and not viral antigen. It is also not a Rapid Antigen Test (RAT) and reportedly requires a certain amount of bio-safety. The single tube, fully multiplexed test comes with two checks in place for Omicron detection and has reported 100% sensitivity and 99.25% specificity for the detection of variants of SARS-CoV-2, including Omicron.

OmiSure can help eliminate the need for genome sequencing to detect Omicron amidst the fresh surge in cases that is exerting pressure on laboratories across the world. The company is also planning to export OmiSure kits and has applied for licensure to the European Union and US Food and Drug Administration (USFDA).

Related Links:
Tata Medical & Diagnostic Centre 

Gold Supplier
SARS-CoV2 Antigen Rapid Test
SARS-CoV2 Antigen Rapid Test
Benchtop Centrifuge
ROTOFIX 46 | 46 H
Live Cell Analysis System
BioTek BioSpa
5-Part Differential Hematology Analyzer
Abacus 5

Print article
IIR Middle East


Molecular Diagnostics

view channel
Image: The ultrarapid genome sequencing pipeline, indicating all processes from sample collection to a diagnosis. Vertically stacked processes are run in parallel (Photo courtesy of Stanford University)

Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting

A genetic diagnosis can guide clinical management and improve prognosis in critically ill patients, and much effort has gone into developing methods that result in rapid, reliable results.... Read more


view channel
Image: My Qualiris QC (Photo courtesy of Stago)

Stago Launches New My Qualiris QC Website for Brand-New User Experience

Stago (Paris, France) has launched its new My Qualiris QC website which provides a brand-new user experience with a 24/7 accessible web-application where the results of a user’s network are only a few clicks away.... Read more


view channel

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.